Brent Saunders didn’t use his first quarterly earnings briefing since returning to Bausch + Lomb Corp.’s helm to list potential targets identified for change and pledge to later provide details on a plan.
With ‘Roadmap To Accelerate Growth,’ Saunders Quick Out Of Gate In Return To Bausch + Lomb
“Multi-year plan with three phases, all with measurable, clear objectives” starts with “rewire company for optimal performance” before moving to “innovate and execute” and then to “accelerate growth,” CEO says.
More from Leadership
• By
HBW Insight catches up with PAGB CEO Michelle Riddalls to chat about the association's new five year plan. Riddalls also reflects on the successes of the last five years, including relaunching the UK Reclassification Alliance, which has published a list of Rx-to-OTC switches the government would like to see applications for. Part one of two.
• By
The departure data emerged along with a Health and Human Services Department memo describing conceptual plans to consolidate and restructure offices at the FDA and other agencies.
• By
A round-up of the latest industry moves in Europe: Pharma Deutschland elects board of new Brussels operation; MHRA's new CEO gets to work; Futura names non-executive director.
• By
The General Services Administration’s updated list of “assets identified for accelerated disposition” does not include any buildings at the agency’s headquarters in White Oak, MD after its original list of “non-core” government properties for disposal had more than half the buildings on campus.
More from HBW Insight
• By
Swiss firm reports highest revenues in its history as restructure pays off for its pharma and cosmetics businesses in 2024.
• By
Industry lobbing for pharmaceuticals to be exempt from President Trump’s sweeping US tariffs appears to have paid off.
• By
The departure data emerged along with a Health and Human Services Department memo describing conceptual plans to consolidate and restructure offices at the FDA and other agencies.